AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00801606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient with zinc
Description: Multimineral 2 RDA and zinc 20 mg per day
Study NCT03729245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bempegaldesleukin
Description: Specified dose on specified days
Study NCT01075022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colecalciferol (Vitamin D3) 300.000 UI
Description: Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
Study NCT03729245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Specified dose on specified days
Study NCT03729245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study NCT03729245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabozantinib
Description: Specified dose on specified days
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF1 tablet
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - TF1 tablet
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF2 tablet
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - TF2 tablet
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - capsules
Study NCT02180477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - capsules
Study NCT03703323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotative thromboelastometry analysis
Description: Obtaining blood sample (one tube of blood)
Study NCT03689855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
Study NCT03689855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
Study NCT03689855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline and Cycle 2 Day 1
Study NCT03689855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan.
Study NCT03148015 — intervention group
Intervention type: OTHER
Intervention: Biomarkers
Description: Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
Study NCT02666612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples
Study NCT02193412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noxious stimulus
Description: standardized noxious stimulus with tetanic stimulation
Study NCT02193412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: change in operating table slope: head-down tilt position
Description: -30°
Study NCT02193412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: change in operating table slope: head-up tilt position
Description: +30°
Study NCT04217213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
Study NCT04217213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Description: In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
Study NCT03074682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifeflow
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
Study NCT03074682 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Push/Pull
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
Study NCT03074682 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Bag
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
Study NCT00989781 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-D Ultrasound
Description: One time pelvic ultrasound
Study NCT00989781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin
Description: Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
Study NCT00989781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone
Description: Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
Study NCT00989781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
Study NCT00989781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given prior to ACTH infusion test.
Study NCT00989781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will undergo 3 oral glcuose tolerance tests.
Study NCT01075022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, Single Dose
Study NCT00795717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
Study NCT00795717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules given twice daily
Study NCT03067701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide
Description: In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
Study NCT01066819 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a [Pegasys]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study NCT01066819 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2b [PegIntron®]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study NCT00801606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01984099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
Study NCT01984099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B Complex
Description: Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
Study NCT01465399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors PRGF-Endoret
Study NCT04222569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
Study NCT01465399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure of the lesion
Study NCT00185692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-myeloablative hematopoietic cell transplantation
Description: TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg PO, 30 minutes prior to infusion Pain reliever
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenydramine
Description: 50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
Study NCT04222569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
Study NCT02473315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
Study NCT00185692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
Study NCT02439892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition during radiotherapy
Description: The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
Study NCT02439892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional rehabilitation after radiotherapy
Description: The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
Study NCT03009318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tumors are confirmed by surgery and pathology
Description: Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
Study NCT00603018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
Study NCT01532869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously weekly, Weeks 0-48
Study NCT01532869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Weeks 0-48
Study NCT00459043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474
Description: Taken orally once every morning
Study NCT00459043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given on the first day of every treatment cycle (every 3 weeks)
Study NCT02982837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN & Nucleos(t)tide analogues
Description: Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
Study NCT02982837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)tide analogues
Description: Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
Study NCT02982837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)tide analogues
Description: Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
Study NCT01532869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Week 48-96
Study NCT01532869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Week 48-96
Study NCT03322670 — intervention group
Intervention type: OTHER
Intervention: Signs of CAP and a positive chest X-Ray
Description: * collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28
Study NCT03322670 — intervention group
Intervention type: OTHER
Intervention: Patients directly hospitalized
Description: * collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90
Study NCT03322670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Control patients
Description: - bacteriological examinations (urine)
Study NCT03322670 — intervention group
Intervention type: OTHER
Intervention: Patients with partial participation
Description: - collection of clinical examination data
Study NCT03322670 — intervention group
Intervention type: OTHER
Intervention: Signs of CAP and a negative chest X-Ray
Description: * collection of clinical examination data~* telephone contact on day 28
Study NCT04314076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic auditory stimulation
Description: RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
Study NCT04314076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait Training
Description: Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone with salmeterol
Description: Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone HFA
Description: Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups
Study NCT02473315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cryotherapy
Description: The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
Study NCT00006478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Study NCT00006478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Study NCT00006478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00006478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT04419038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with topical application of Mitomycin C
Description: Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
Study NCT04419038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with Ologen implantation
Description: Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
Study NCT01328756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
Study NCT04127747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of rituximab
Description: Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
Study NCT04127747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized dose of rituximab
Description: Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
Study NCT02333565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02333565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT03471117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg daily for 1 month
Study NCT03471117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 1 month